Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Aug. 16 to 20, 2021. This […]
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Aug. 16 to 20, 2021. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
Long-Haul COVID-19 May Affect Two of Three With Mild, Moderate Disease
FRIDAY, Aug. 20, 2021 (HealthDay News) — The majority of individuals who experience mild or moderate COVID-19 infection have persistent symptoms more than 30 days after diagnosis, according to a study published online Aug. 4 in PLOS ONE.
COVID-19 Immune Response Appears Strong in Cancer Patients
FRIDAY, Aug. 20, 2021 (HealthDay News) — The seropositivity rate among patients with cancer remains high four months after the second dose of the COVID-19 vaccine, according to a research letter published online Aug. 11 in JAMA Oncology.
Risk for Myocarditis in Young Who Get Moderna Shots May Be Greater Than Thought
FRIDAY, Aug. 20, 2021 (HealthDay News) — The Moderna COVID-19 vaccine may be linked to a higher risk for myocarditis in younger adults than believed, emerging reports show.
Decision on J&J COVID-19 Vaccine Booster Doses Could Take Weeks
FRIDAY, Aug. 20, 2021 (HealthDay News) — A decision on booster shots for the approximately 13.8 million Americans who received the Johnson & Johnson single-shot COVID-19 vaccine is likely to take weeks, according to people familiar with the issue.
mRNA COVID-19 Vaccine Effectiveness Lower During Delta Strain Era
FRIDAY, Aug. 20, 2021 (HealthDay News) — mRNA COVID-19 vaccines provide protection against infection among nursing home residents, but the vaccine effectiveness was lower after the delta variant became the predominant strain, according to research published in the Aug. 18 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
mRNA Vaccine Effective Against Hospitalization Over 24-Week Period
FRIDAY, Aug. 20, 2021 (HealthDay News) — The effectiveness of mRNA vaccination against COVID-19-associated hospitalization is sustained over a 24-week period, according to research published in the Aug. 18 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Screening Mammograms Plummeted During COVID-19 Pandemic
FRIDAY, Aug. 20, 2021 (HealthDay News) — Substantially fewer women completed screening mammograms at one safety-net hospital during the first year of the pandemic, with Black women experiencing the lowest volumes compared with other racial/ethnic groups, according to a research letter published online Aug. 6 in JAMA Network Open.
COVID-19 Vaccine Effectiveness Down Against New Infections in New York
Trends Reported in Vaccination Coverage for Adolescents for 2025 
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season 
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
Social Media Warnings Could Discourage Use Among Teens, Young Adults 
Digital Behavioral Health Game Reduces Depressive Symptoms in Teens .jpeg)
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay 
Reinitiating Obesity Meds After Bariatric Surgery Tied to Greater One-Year Weight Loss in Youths 
